Myelofibrosis
is a disease characterized by the build-up of scar tissue in the bone marrow, which
leads to genetic mutation in a person’s body. The myelofibrosis therapeutics
pipeline is anticipated to increase with the growing need to develop a cure for
the problem, and is noticed in approximately one in 500,000 people, in the U.S.,
usually in the age group of 50 to 80 years, as per the as data provided by U.S.
national Library of Medicine. It is a rare form of disease and also happens to
patients with thrombocythemia and polycythemia. Moreover, the future
developments in therapies are expected to shoot-up.
Explore Report at: https://www.psmarketresearch.com/market-analysis/myelofibrosis-therapeutics-pipeline-analysis
According
to National Center for Advancing Translational Sciences, myelofibrosis is
disorder of bone marrow, in which bone marrow is replaced by fibrous tissues.
In myelofibrosis, bone marrow cannot produce sufficient blood cells and
platelets, which leads to weakness, anemia, fatigue and sometimes swelling of
spleen and liver. Reduction in number of platelets can cause bleeding and
bruising. This condition is also called extramedullary haematopoiesis. The
genes of the stem cells such as, JAK2, MPL, CALR, and TET2 genes undergo
mutation in somatic stem cells but, the condition is uninherited. Treatments for
the problem include chemotherapy, radiation therapy, blood transfusion and
surgery.
In
November 2013, Baxter International Inc. entered into a licensing agreement
with Cell Therapeutics, Inc., to develop and commercialize - pacritinib.
Pacritinib is a novel investigational JAK2/FLT3 inhibitor with activity against
genetic mutations linked to myelofibrosis, leukemia and certain solid tumors. Pacritinib
is currently in Phase II clinical development in patients having chronic malignant
bone marrow disorder, myelofibrosis.
No comments:
Post a Comment